AdvaMed, MDMA Support, but Express Concerns Over CMS Coverage of Breakthrough Devices

AdvaMed and the Medical Device Manufacturers Association (MDMA) commented this week on a CMS notice expediting Medicare coverage of emerging technologies, urging swift acceptance of the program, but also arguing that the proposal is limited in nature and doesn’t cover enough innovative devices.
Source: Drug Industry Daily

Leave a Comment





This site uses Akismet to reduce spam. Learn how your comment data is processed.